Effects of Fermented Soya Bean Supplements on Serum Insulin and Leptin Levels of High Fat Diet-induced Type 2 Diabetes Mellitus in Rabbits

Background: Increase in body fat and obesity are the main risk factors for type 2 diabetes mellitus which leads to several complications that affect many organs of the body when poorly controlled. Plant food sources rich in fibre and antioxidants play an important role in the management of diabetes mellitus. This study aimed to evaluate the effects of fermented soya bean supplements on serum insulin and leptin levels of high fat diet-induced type 2 diabetes mellitus in rabbits. Methods: Twenty rabbits of both sexes weighing, 1–2kg were used. Type 2 diabetes was induced by feeding the animals with a high fat diet for eight weeks. Blood glucose levels were determined after the induction period and rabbits having 130 mg/dL and above were selected for the study. The animals were grouped into four groups with five (n=5) rabbits in each group: Group 1 (diabetic control), received distilled water ad libitum for six weeks; Groups 2, 3 and 4 (diabetic rabbits) were fed with 12.5%, 25% and 50% fermented soya bean supplements respectively for a period of six weeks. Fasting blood glucose levels were determined at weekly interval during the treatment period. At the end of the experiment, the rabbits were euthanized by cervical dislocation and blood samples were collected for the determination of insulin, and leptin levels. Data obtained were analysed using ANOVA. Results: The result showed a significant decrease (P≤0.05) in leptin levels (ng/mL) in groups 2, 3 and 4 (11.30 ± 0.20, 9.20 ± 2.06 and 6.40 ± 1.36, respectively) as compared with the control (18.8 ± 1.59). Insulin levels were also decreased in all the treated groups when compared with the control, though not statistically significant, it may be biologically significant. Conclusion: The results of the study show that fermented soya bean supplementation possesses anti-diabetic properties and may help in the control of hyperleptinaemi

The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance

INTRODUCTION Investment in Africa over the past year with regard to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing has led to a massive increase in the number of sequences, which, to date, exceeds 100,000 sequences generated to track the pandemic on the continent. These sequences have profoundly affected how public health officials in Africa have navigated the COVID-19 pandemic. RATIONALE We demonstrate how the first 100,000 SARS-CoV-2 sequences from Africa have helped monitor the epidemic on the continent, how genomic surveillance expanded over the course of the pandemic, and how we adapted our sequencing methods to deal with an evolving virus. Finally, we also examine how viral lineages have spread across the continent in a phylogeographic framework to gain insights into the underlying temporal and spatial transmission dynamics for several variants of concern (VOCs). RESULTS Our results indicate that the number of countries in Africa that can sequence the virus within their own borders is growing and that this is coupled with a shorter turnaround time from the time of sampling to sequence submission. Ongoing evolution necessitated the continual updating of primer sets, and, as a result, eight primer sets were designed in tandem with viral evolution and used to ensure effective sequencing of the virus. The pandemic unfolded through multiple waves of infection that were each driven by distinct genetic lineages, with B.1-like ancestral strains associated with the first pandemic wave of infections in 2020. Successive waves on the continent were fueled by different VOCs, with Alpha and Beta cocirculating in distinct spatial patterns during the second wave and Delta and Omicron affecting the whole continent during the third and fourth waves, respectively. Phylogeographic reconstruction points toward distinct differences in viral importation and exportation patterns associated with the Alpha, Beta, Delta, and Omicron variants and subvariants, when considering both Africa versus the rest of the world and viral dissemination within the continent. Our epidemiological and phylogenetic inferences therefore underscore the heterogeneous nature of the pandemic on the continent and highlight key insights and challenges, for instance, recognizing the limitations of low testing proportions. We also highlight the early warning capacity that genomic surveillance in Africa has had for the rest of the world with the detection of new lineages and variants, the most recent being the characterization of various Omicron subvariants. CONCLUSION Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve. This is important not only to help combat SARS-CoV-2 on the continent but also because it can be used as a platform to help address the many emerging and reemerging infectious disease threats in Africa. In particular, capacity building for local sequencing within countries or within the continent should be prioritized because this is generally associated with shorter turnaround times, providing the most benefit to local public health authorities tasked with pandemic response and mitigation and allowing for the fastest reaction to localized outbreaks. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century

Assessing the Effects of Coronavirus Outbreaks on the Demand for Electronic Health In Nigeria

Electronic health (e-Health) and Mobile health (m-Health) is perceived as opportunity for patients to access their health care providers in the developing countries during coronavirus pandemic as it has been found to contribute tremendously to health care provision in the developed world even before the pandemic. This study attempts to assess how residents of developing countries annexe e-health and m-health during coronavirus outbreak. More specifically, the study analyses the demand for and adoption of electronic health in the face of coronavirus pandemic in Nigeria (a developing country) using Borgu local government, Niger state as case study. It was found that during the outbreak, residents of the local government did not significantly adopt electronic health during the pandemic majorly due to access to community health worker and cost of adopting electronic health facilities. It was recommended that government and relevant health care agencies that deal policy formulation take necessary measure to encourage wider acceptance of electronic health in Nigeria

Rivaroxaban with or without aspirin in stable cardiovascular disease

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events